



Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand). This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library

[Thesis Consent Form](#)

Mechanical properties of passive rat cardiac trabeculae.

By Robert S. Kirton

Supervised by Dr. Poul Nielsen
and Dr Denis Loiseau

A thesis submitted in partial fulfillment of the requirements for the degree
of Doctor of Philosophy at the University of Auckland



Department of Engineering Science and the Bioengineering Institute
School of Engineering.

The University of Auckland

January 2005

Abstract

In this thesis, the mechanical properties of quiescent, intact, viable, rat right-ventricular (RV) trabeculae were investigated. The main objective was to determine if strain-softening, which is commonly reported during the deformation of passive cardiac tissue, is present in viable trabeculae. Strain-softening is typically manifested by a stiffer force-extension relation in the first deformation cycle relative to subsequent cycles, and is distinguished from viscoelasticity by a lack of recovery of stiffness, even after several hours of rest. The causes of this behaviour are unknown.

To investigate whether strain-softening is observed during uniaxial extensions of viable cardiac tissue, stretch and release cycles of 5%, 10% and 15% muscle length were applied at a constant velocity to trabeculae mounted in a mechanical rig. The rig was custom-built for the purpose. Muscles at 26°C and 0.5 mM Ca^{2+} were tested in random order in the presence and absence of 50 mM 2,3-butanedione monoxime (BDM).

Strain-softening was not observed in viable trabeculae undergoing physiologically relevant extensions, either in the presence or absence of BDM. However, strain-softening was readily apparent in non-viable trabeculae undergoing the same levels of extension, whether in the presence or absence of BDM. BDM had no effect on passive compliance of viable specimens, while its presence partially inhibited, but could not prevent, stiffening of the non-viable specimens. Loss of viability was accompanied by a uniform increase of dynamic stiffness. The presence of strain-softening during length extensions of non-viable tissue, resulted in a uniform decrease of dynamic stiffness. It is

therefore concluded that strain-softening is neither intrinsic to viable rat RV trabeculae nor influenced by BDM but, rather, reflects irreversible damage of tissue in partial, or full, rigor.

The addition of BDM was found to alter the dynamic stiffness and phase measured in intact viable quiescent trabeculae. In the absence of BDM, these alterations were calcium- and temperature-sensitive, whereas in the presence of BDM they were not. Therefore, the BDM-induced alteration of the dynamic stiffness and phase is attributed to the inhibition of spontaneous sarcomere activity.

Acknowledgments

During the course of my Ph.D., I have received encouragement and support from my family, colleagues and friends.

My supervisors, Drs Denis Loiselle and Poul Nielsen, and my colleague Dr Andrew Taberner, have helped shape my scientific abilities by offering: support, encouragement and enough space to conceive ideas while supplying the required critical feed back. I appreciate their interest in my personal life as well as my scientific progress. I was continually amazed by the seemingly endless supply of novel and creative ideas from Poul. I applaud the patience shown by Denis when introducing me to the world of statistical analysis. I am indebted to Andrew for his enthusiasm, ideas, technical and scientific input and friendship. His LabView and Hardware development, as well as his “lets get going” attitude, ensured the success of the project, and my Ph.D.

I must thank both Dr Alistair Young, as the ‘few’ experiments he suggesting help refocus the studies within this Thesis, and Dr David Budgett, who helped me focus on what was really important. The critical scientific feedback from Professor Peter Hunter, Dr Ian Legrice and Associate Professor Bruce Smaill was always gratefully accepted.

The Royal Society of New Zealand (Marsden Fund), Health Research Council of New Zealand, Bioengineering Institute and the Department of Engineering Science have been sources of generous financial support.

Both the Bioengineering Institute and the department of Engineering Science have provided a supportive and enjoyable environment for academic growth. The fifth floor lab dwellers (Adele, Aneela, Duane, Karin, Kevin, Mark, Paul and Paul, Sharif, Vince, Wayne and Yme) have supplied entertaining and valuable scientific, social and political interactions.

My Mum and Dad, and the rest of my family, for the encouragement and support you have continually offered. Dad, you were correct when you said it was a test of endurance, and I am sorry you are not here to see the results. My friends Mark, Debbie, Meg, Chris and Steve who have provided support for many years, and have been neglected of late. Denis, Poul, Adele, Yme, Meg and Leanne all freely donated proof reading time.

I thank my partner and dearest friend, Leanne Luxford. She has generously and patiently supplied support, love and encouragement, all of which allowed me to complete this work. I have also greatly benefited from distractions, laughter and love, generously supplied by our daughters, Jessica and Emily.

Table of Contents

Abstract	iii
Acknowledgments	v
Table of Contents.....	vii
List of Figures	xi
List of Tables.....	xiii
List of Abbreviations and Symbols	xv
Chapter One: Introduction and Literature Review... 1	
1.1 General overview.....	1
1.2 The functioning heart.....	2
1.2.1 The heart as a pump.	2
1.2.2 Structure of the heart.	4
1.2.3 Intracellular contractile mechanisms.	6
1.3 Measurement of passive myocardium.....	9
1.4 The trabecula as a muscle preparation.	14
1.5 Structural basis of passive tension.	16
1.6 Strain-softening.....	19
1.7 Tissue viability.....	23
1.8 The effects of 2,3-butanedione monoxime (BDM). 24	
1.8.1 Cardioprotective properties of BDM.	25
1.8.2 Effect of BDM on mechanical properties of striated-muscle.	25
1.9 Thesis objectives.....	27
Chapter Two: Methods and Materials..... 29	
2.1 Muscle preparation and solutions.	29
2.1.1 Muscle preparation.	29
2.1.2 Solutions.	32
2.2 Muscle bath and mechanical testing apparatus.	33
2.2.1 Requirements and specifications.	33

2.2.2 Data acquisition and experimental control.	33
2.2.3 Open-ended muscle bath.	34
2.2.4 Length perturbation and force measurement.	41
2.2.5 Muscle-rig optical systems.	45
2.3 Experimental procedures and protocols.	49
2.3.1 Muscle mounting and viability check.	50
2.3.2 Muscle scanning.	51
2.3.3 Passive stress-muscle length extension.	52
2.3.4 Dynamic stiffness.	53
Chapter Three: Absence of Strain-Softening in Viable Trabeculae.	57
3.1 Introduction.	57
3.2 Methods and materials.	61
3.2.1 Muscle preparation and solutions.	61
3.2.2 Muscle bath and superfusate system.	62
3.2.3 Data acquisition and experimental control.	62
3.2.4 Muscle attachment.	62
3.2.5 Force measurement.	63
3.2.6 Mechanical perturbation system.	63
3.2.7 Optical systems.	63
3.2.8 Muscle stabilisation.	64
3.2.9 Experimental protocols.	64
3.2.10 Statistical analysis.	65
3.3 Results.	67
3.3.1 Testing for strain-softening.	67
3.3.2 Effect of BDM on tissue compliance.	73
3.4 Discussion.	75
3.4.1 Strain-softening.	75
3.4.2 Effect of BDM on tissue compliance.	80
3.4.3 Limitations.	81
3.4.4 Conclusions.	82
Chapter Four: Strain-Softening in Electrically Non-Responsive (Non-Viable) Trabeculae.	83
4.1 Introduction.	83
4.2 Methods and materials.	87

4.2.1 Muscle preparation and solutions.	87
4.2.2 Mechanical perturbation system.	87
4.2.3 Optical systems.	90
4.2.4 Mounting the muscle.	90
4.2.5 Passive stress-strain protocols.	90
4.2.6 Statistical analysis.	91
4.3 Results.	92
4.3.1 Stress-ML relations in viable and non-viable trabeculae.	92
4.3.2 Effect of BDM on compliance of non-viable trabeculae.	97
4.3.3 Dynamic stiffness of viable and non-viable trabeculae.	102
4.3.4 Test of strain-softening irreversibility.	104
4.4 Discussion.	105
4.4.1 Strain-softening in non-viable tissue.	106
4.4.2 Influence of BDM on strain-softening and tissue compliance.	116
4.4.3 Limitations and future work.	117
4.4.4 Conclusions.	118
Chapter Five: Effect of BDM on the Dynamic Stiffness of Quiescent Cardiac Trabeculae.....	119
5.1 Introduction.	119
5.2 Methods and materials.....	121
5.3 Results.	125
5.4 Discussion.	134
5.4.1 Conclusions.	141
Chapter Six: Conclusions and Future work.....	143
6.1 Clinical relevance.	150
6.2 Future studies	150
References	153

List of Figures

Figure 1.1. Diagram of the heart.	3
Figure 1.2. Pressure volume relationship.	4
Figure 1.3. Schematic of two adjacent sarcomeres.	7
Figure 1.4. The myofilament proteins.	9
Figure 1.5. A rat cardiac trabecula.	14
Figure 1.6. Left ventricular pressure-volume relations showing strain-softening.	22
Figure 2.1. Typical location of trabecula in the right ventricular wall.	30
Figure 2.2. The muscle bath.	34
Figure 2.3. The computer interface for the Temperature Monitor program.	37
Figure 2.4. Glass hook.	38
Figure 2.5. The force transducer.	41
Figure 2.6. The muscle perturbation hardware.	43
Figure 2.7. The monitoring microscope system.	45
Figure 2.8. The sarcomere length imaging microscope.	46
Figure 2.9. Determination of sarcomere length.	48
Figure 2.10. Typical force response of cardiac trabeculae to electrical stimulation	50
Figure 2.11. One Set of uniaxial length extensions	51
Figure 2.12. Protocol and force responses for dynamic stiffness and phase measurement.	53
Figure 2.13. Comparison of stiffness spectra acquired using PRBN and sinusoids.	54
Figure 3.1. Schematic of irreversible strain-softening.	56
Figure 3.2. Typical stress-ML extension data for 5%, 10% and 15% Stretch.	66
Figure 3.3. Stress-ML relations for 15% extensions in +BDM and -BDM.	67
Figure 3.4. Stress-SL and SL-ML relations.	68
Figure 3.5. Mean stress/cycle, at 3.5% and 7% ML for Set 1 and 2.	70
Figure 3.6. Stress-ML relation for a non-viable trabecula.	71
Figure 3.7. Mean stress/cycle, at 3.5% and 7% ML in +BDM and -BDM.	72
Figure 4.1. Schematic of sinusoidal ML perturbations and resulting force changes.	88
Figure 4.2. Definition of dynamic stiffness.	88
Figure 4.3. Stress-ML relations for a trabecula when viable, and non-viable.	92
Figure 4.4. Stress-ML relations during onset of rigor.	92
Figure 4.5. Mean stress/cycle, for viable and non-viable trabeculae at 3.5% and 7% ML.	93
Figure 4.6. Mean passive tension during stretch cycles of non-viable trabeculae.	95
Figure 4.7. Mean stress/cycle at 3.5% ML of 15% Stretch, for non-viable trabeculae (-BDM+O ₂ , +BDM+O ₂ , +BDM-O ₂).	97
Figure 4.8. Mean passive stress, during Stretch of 3 groups of non-viable trabeculae.	99
Figure 4.9. 'Stress-differences' for 15% Stretch of trabecula when viable and non-viable.	100
Figure 4.10. Typical stress-ML and stress-difference relations for non-viable trabecula.	100
Figure 4.11. Stiffness and phase spectra of trabecula when quiescent, Ba ²⁺ -activated and in rigor	101
Figure 4.12. Changes in dynamic stiffness and phase spectra during strain-softening.	102
Figure 4.13. Stress-ML relations, during 25% and then 17% ML extension in non-viable trabecula.	103
Figure 5.1. Dynamic stiffness and phase spectra for trabecula, when Ba ²⁺ activated, and quiescent +BDM and -BDM.	125

Figure 5.2. Mean stiffness and phase spectra in +BDM and -BDM.	126
Figure 5.3. Mean stiffness and phase spectra of 3 groups, in +BDM and -BDM.	127
Figure 5.4. Mean stiffness-ratio and phase-difference spectra for Group 1.	129
Figure 5.5. Mean stiffness-ratio and phase-difference spectra for Groups 1, 2 and 3.	130
Figure 5.6. Indices of cross-bridge cycling for Groups 1, 2 and 3, in +BDM and -BDM.	131
Figure 5.7. Mean stiffness-ratio and phase difference spectra under osmotic stress.	132

List of Tables

Table 2.1. Results of sarcomere length calculation software.	47
Table 3.1. ANOVA probabilities of stress at 3.5% and 7% ML, for Set 1 and Set 2.	69
Table 3.2. ANOVA probabilities of stress at 3.5% and 7% ML, for +BDM and -BDM.	73
Table 4.1. ANOVA probabilities of stress at 3.5% and 7% ML, for non-viable trabeculae.	94
Table 4.2. Mean stress decrement between C1-5% and C6-5%, -10% and -15%.	96
Table 4.3. ANOVA probabilities of stress at 3.5% and 7% ML, for non-viable trabeculae including three groups.	98
Table 4.4. ANOVA probabilities of stress at 3.5% and 7% ML, for each of three groups of non-viable trabeculae.	98
Table 4.5. Linear regression analysis of passive stress versus stiffness.	103
Table 5.1. The solution compositions used in study.	122
Table 5.2. ANOVA probabilities of Ca ²⁺ , Temp, Freq and BDM on dynamic stiffness and phase.	128
Table 5.3. ANOVA probabilities of Ca ²⁺ , Temp, Freq and BDM stiff.-ratios and phase-diff.	130
Table 5.4. ANOVA of Freq, BDM and BDM*Freq on stiffness, phase, stiff.-ratios and phase-diff. for osmotic stress.	133
Table 6.1. Comparison of load-dependence of various preparations.	145

List of Abbreviations and Symbols

°C	Degrees Celsius
ADP	Adenosine diphosphate
ATP	Adenosine triphosphate
AV	Atrioventricular
Ba ²⁺	Barium ion.
BDM	2,3-Butanedione monoxime
Ca ²⁺	Calcium ion
[Ca ²⁺] _i	Intercellular calcium concentration
[Ca ²⁺] _o	Extracellular calcium concentrations
CICR	Calcium Induced Calcium Release
D/A	Digital to Analogue conversion
FEM	Finite element modelling
F	Frequency (Hz)
f _{min}	Frequency at which muscle stiffness is a minimum.
Hz	Hertz
IndexXB	Index of cross-bridge cycling.
<i>k</i> ₁₀₀	Stiffness at 100 Hz
<i>k</i> _∞	High frequency stiffness
LAD	Left anterior descending coronary artery
LAL	Left atrial ligation
N/m	Newtons per meter, or Pascals.
min	Minutes
ML	Muscle length
mM	milli molar
pHi	Intracellular pH.
PI	Physik Instrumente linear actuator
P _i	Inorganic phosphate.
PRBN	Pseudo random binary noise
RV	Right Ventricular
s	Seconds
SL	Sarcomere length
SNR	Signal to Noise Ratio
TnC	Troponin C
TnI	Troponin I
TnT	Troponin T

